MEDIA

Media Inquiries

Gem Hopkins

Ghopkins@OncoSec.com

858-210-7334

Press Releases

VIEW ALL PRESS RELEASES

Video Feed

3D MOA Animation video

✕

OncoSec's VLA 3D MOA Animation

✕

TAVO Demonstration with Dr Algazi

✕

OncoSec at 2020 BIO CEO Panel

✕

Tumor Immunogenicity

✕

IAD Reel

✕

IAD Robert Andtbacka, M.D.

✕

Social Media

Twitter Feed

OncoSec Medical@OncoSec·
14h

.@ad1600 of @UCSFCancer explains our KEYNOTE-695 #clinicaltrial, using our investigational product #TAVOᵀᴹ in combination with #KEYTRUDA® to potentially treat #melanoma. Listen to Dr. Daud's full description here: https://event.on24.com/wcc/r/2345516/B6AD55C4589FCE8B2787793FB5319FF6 #TogetherAgainstCancer

OncoSec Medical@OncoSec·
30 Jun

After 2 decades working in the CRO industry, our Chief Clinical Development Officer, Kellie Malloy Foerter, is applying her expertise to guide our clinical development programs for #cancer with limited treatment options. Learn more: https://www.pharmavoice.com/wow-podcasts/wow-kellie-malloy-foerter/ #TogetherAgainstCancer

OncoSec Medical@OncoSec·
29 Jun

Recently, @cancerhealthmag explored our data published in @CCR_AACR showing our investigational candidate, #TAVO™, with KEYTRUDA® produced a 41% overall response rate and 36% complete response in late-stage #metastatic #melanoma: https://www.cancerhealth.com/article/interleukin12-electroporation-may-sensitize-cold-melanomas-immune-checkpoint-inhibition
#TogetherAgainstCancer

OncoSec Medical@OncoSec·
26 Jun

According to @theNCI, #SkinCancer is the most common #cancer. Visit https://oncosec.com/ to learn more about our commitment to deliver safer and more effective treatments for #metastatic #melanoma and other types of cancer. #TogetherAgainstCancer

Featured Articles

Melanoma Research Alliance

From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate

PharmaVoice

Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.